Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Cough
Interventions
DRUG

Rengalin

Solution for oral administration

DRUG

Placebo

Solution for oral administration

Trial Locations (14)

119991

First Moscow State Medical University named after I.M. Sechenov, Moscow

129515

"Llc Diagnosis and Vaccines", Moscow

150030

Clinical Hospital # 2, Yaroslavl

188300

Gatchina Clinical Interdistrict Hospital, Gatchina

191144

Children's City Polyclinic # 44, Saint Petersburg

196191

Children's City Polyclinic # 35, Saint Petersburg

344011

"Clinical and diagnostic center Health in Rostov-on-Don", Rostov-on-Don

350015

Specialized Clinical Infectious Diseases Hospital, Krasnodar

410064

Saratov City Children's Clinical Hospital, Saratov

420097

"Llc Medlight", Kazan'

443079

Samara Regional Children's Clinical Hospital named after N.N. Ivanova, Samara

614066

City Children's Clinical Polyclinic # 5, Perm

614070

"LLC Professor's Clinic", Perm

620028

Children's City Clinical Hospital # 11, Yekaterinburg

Sponsors
All Listed Sponsors
lead

Materia Medica Holding

INDUSTRY

NCT07171099 - Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children | Biotech Hunter | Biotech Hunter